Aeon Acquires Germany's Aware Health As Seed Funding Tops $14M

Aeon, a Zurich based preventive healthcare company, has closed an extension of its seed round and used the moment to acquire the core assets of Aware Health, one of Germany's leading consumer blood diagnostics platforms.

The seed extension was co‑led by Araya Ventures, with participation from existing investors Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital and Bigwave Capital. The new capital brings Aeon's total seed funding to more than 14 million dollars, following an initial 8.2 million euro seed round closed in June 2025 that was led by Concentric.

Aeon was founded in 2023 by Tim Seithe, a physician who previously built and sold Tillhub to KKR owned Unzer, alongside chief product officer Samuel Frey. The company's platform combines whole‑body MRI screening, capable of examining more than 500 possible abnormalities across the brain, organs and blood vessels, with blood diagnostics covering more than 100 biomarkers and AI based risk assessment. Aeon has been live in Germany since early 2026, and the company has said the market has already become its fastest growing one.

The problem Aeon has been working to solve is that its core screening tool, whole‑body MRI, produces a powerful but essentially one‑off snapshot. Blood testing, by contrast, can be repeated regularly, which makes it a better foundation for tracking how a person's health changes over time rather than capturing a single point in time. Aware Health, the Berlin company Aeon has now acquired, built a fully regulated consumer blood diagnostics stack around exactly that recurring model, with live laboratory integrations and a network of more than 45 blood‑draw locations across Germany, serving close to 10,000 active customers across a wide range of preventive health test panels.

Through the acquisition, Aeon gains Aware's full technology platform, its key contracts and lab equipment, its customer relationships and its core team, which will continue operating from Berlin under the Aeon brand without interruption. Company executives have said the acquired infrastructure, including blood collection sites, laboratory integrations and regulatory approvals, would otherwise have taken Aeon several years to build on its own. It is the second acquisition for Aeon, following last year's purchase of Swiss stealth‑mode company Holsain, whose MRI body composition screening work brought Holsain founder Florian Alexander Huber into Aeon as chief medical officer.

Handling of the acquired customer data has been treated carefully in how the deal has been described. The companies have said that Aware's existing customer data will not automatically transfer as part of the transaction, and any transfer will only happen with each customer's explicit individual consent and in compliance with the General Data Protection Regulation. That distinction matters for Aeon's longer term ambitions, since the longitudinal biomarker dataset built up through Aware's recurring testing is intended to become part of the raw material used to train Aeon's predictive AI models, a use case that depends on data being gathered with clear and specific consent rather than inherited automatically through an acquisition.

Alongside the deal, Aeon has been building out its AI team, adding Pablo Tano as AI lead. Tano has published research on reinforcement learning in the brain in Nature, co‑authored work with researchers including Peter Dayan and Alexandre Pouget, and was part of a winning team in Meta's MyoChallenge. At Aeon, he takes ownership of the models intended to read across imaging, blood biomarkers and genetic data together, the technical core of what the company is betting will differentiate its platform from single‑modality competitors.

Rupa Popat, general partner at Araya Ventures, has described the combination of imaging, recurring blood diagnostics and AI as creating a longitudinal health picture unmatched by any other platform in Europe. That claim sits within a crowded and fast moving European preventive diagnostics field. Fellow Zurich company Ahead Health raised 5.1 million euros in January and a further 8.7 million euros in July for a similar mix of blood testing, whole‑body imaging and AI, while Paris‑based Lucis raised around 17 million euros in the same category. Smaller rounds have also landed for adjacent diagnostics players, including 2.8 million euros for Moonlight AI, 5 million euros for En Carta Diagnostics and 15 million euros for iPremom, underlining how much investor capital is currently flowing into AI powered preventive health across Europe.

Seithe has framed the Aware acquisition as accelerating Aeon's roadmap by roughly two years, arguing that imaging shows where a person's health stands today while recurring blood diagnostics show where it is heading, with AI serving as the layer that connects the two into genuine prediction. More than 90 percent of Aeon's check‑ups already surface findings that customers can act on, according to the company, a figure that will be tested at greater scale as Aware's blood‑draw network and customer base become part of daily operations. Whether combining episodic imaging with recurring diagnostics under one brand proves durable, rather than something well funded rivals replicate through partnerships of their own, will likely become clearer as Aeon works through the operational task of integrating two companies' infrastructure, regulatory approvals and teams across two countries.